Groundbreaking Results: Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111).
Positive Topline Results For Autoimmune…
Groundbreaking Results: Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111).